Navigating Immune-related Adverse Events in Metastatic Triple-Negative Breast Cancer

This chapter delves into the management of metastatic triple-negative breast cancer with pembrolizumab, focusing on immune-related adverse events, patient response monitoring, and potential treatment adjustments. The speakers discuss correlations between significant immune-related toxicities and treatment efficacy, as well as the challenges of offering immunotherapy to patients with underlying autoimmune conditions or prior transplants.